These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8380528)

  • 1. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations.
    Forno LS; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1993; 60():600-8. PubMed ID: 8380528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
    Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
    Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey.
    Forno LS; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1996; 69():217-28. PubMed ID: 8615131
    [No Abstract]   [Full Text] [Related]  

  • 4. The Lewy body in Parkinson's disease.
    Forno LS
    Adv Neurol; 1987; 45():35-43. PubMed ID: 3030070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.
    Meredith GE; Halliday GM; Totterdell S
    Parkinsonism Relat Disord; 2004 Jun; 10(4):191-202. PubMed ID: 15120093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
    Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
    Fox SH; Brotchie JM
    Prog Brain Res; 2010; 184():133-57. PubMed ID: 20887873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of MPTP toxicity.
    Przedborski S; Jackson-Lewis V
    Mov Disord; 1998; 13 Suppl 1():35-8. PubMed ID: 9613716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.
    Halliday G; Herrero MT; Murphy K; McCann H; Ros-Bernal F; Barcia C; Mori H; Blesa FJ; Obeso JA
    Mov Disord; 2009 Jul; 24(10):1519-23. PubMed ID: 19526568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
    Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
    Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuropathology of the basal ganglia in Parkinson's disease with a special reference to its responsible lesion].
    Tanaka J; Fukuda T
    Nihon Rinsho; 1997 Jan; 55(1):32-8. PubMed ID: 9014420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
    Shimoji M; Zhang L; Mandir AS; Dawson VL; Dawson TM
    Brain Res Mol Brain Res; 2005 Mar; 134(1):103-8. PubMed ID: 15790534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dementia and neuropathology in Lewy body disease.
    Kosaka K
    Adv Neurol; 1993; 60():456-63. PubMed ID: 8420170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic Parkinson's disease: a review of clinical types and pathology.
    Olasode BJ
    Niger J Med; 2001; 10(3):116-20. PubMed ID: 11806009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
    Song DD; Shults CW; Sisk A; Rockenstein E; Masliah E
    Exp Neurol; 2004 Apr; 186(2):158-72. PubMed ID: 15026254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [MPTP: a new chapter in the history of Parkinson's disease].
    Piccinin GL; Piccirilli M; Finali G; Stefano E
    Riv Neurol; 1989; 59(3):103-7. PubMed ID: 2688042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease.
    Brownell AL; Jenkins BG; Isacson O
    Biomed Pharmacother; 1999 Apr; 53(3):131-40. PubMed ID: 10349501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lewy bodies in Betz cells of the motor cortex in a patient with Parkinson's disease.
    Wakabayashi K; Mori F; Oyama Y; Kurihara A; Kamada M; Yoshimoto M; Takahashi H
    Acta Neuropathol; 2003 Feb; 105(2):189-92. PubMed ID: 12536231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lewy bodies, a misleading marker for Parkinson's disease?].
    Duyckaerts C; Hauw JJ
    Bull Acad Natl Med; 2003; 187(2):277-92; discussion 292-3. PubMed ID: 14556441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.